Moderna announced on Wednesday,⁣ October 23, 2024, that its experimental vaccine for cytomegalovirus (CMV) failed to meet its primary endpoint in a Phase 3 ⁣clinical trial. This represents a significant setback for the company,⁢ which had previously identified⁤ the CMV vaccine as a key growth driver. The declaration came as Moderna faces ⁣increasing scrutiny from Wall Street and the federal government regarding⁤ its post-COVID vaccine strategy.

CMV is a ‍common virus that typically causes mild or no symptoms in healthy people. However, it can be devastating for newborns, potentially leading to hearing loss, developmental disabilities, and even death.Prior to the COVID-19 pandemic, the CMV vaccine was Moderna’s leading pipeline program.

Financial Implications and Previous Projections

Moderna leadership had consistently projected significant revenue potential for the CMV vaccine, estimating peak annual sales between $2 billion and $5 billion. ⁢ Financial analysts polled by Visible‍ Alpha offered a more conservative estimate,forecasting peak sales of $1.6 billion. The failure of the Phase 3 trial casts significant doubt on these projections.

The news sent Moderna’s stock price down in after-hours trading on Wednesday. The company is already ⁣under pressure to demonstrate its ability ⁢to generate ‍revenue beyond its COVID-19⁤ vaccine, which has seen declining demand.

Moderna’s Response

“It’s obviously disappointing,” stated ⁤Stephen Hoge, ⁢Moderna’s⁣ president, in an interview following the announcement.The ⁣company‍ has not yet released detailed data from the Phase 3 trial, but indicated it would be analyzed to understand the ⁣reasons for the failure and explore potential next steps.

Understanding Cytomegalovirus (CMV)

CMV is a member of the herpesvirus family and is ⁣extremely common. According to the Centers for Disease Control and Prevention (CDC), more than half of all people are infected with CMV by the time they reach ‍adulthood. Most people never know they⁢ are‍ infected.

Though, CMV infection ⁣during ⁣pregnancy can ⁣be dangerous for the developing fetus. Congenital CMV infection is the leading non-genetic cause of hearing loss and a significant ⁢cause of intellectual disability in children.‍ Approximately 1 in‍ 750 babies‍ are born with congenital CMV infection each year in the united States.